With a vision of conquering GI disease, Vivelix is committed to delivering innovative products and services that improve the lives of patients suffering from gastrointestinal and liver diseases.
Formed in March 2016, Vivelix is founded and staffed by an experienced team of gastroenterology drug developers and marketers, and funded by private equity investment.
The leadership team includes eight former employees of Salix Pharmaceuticals, Inc. with more than 165 years of collective clinical, drug development, business development and commercialization experience, including over 75 years of experience in gastroenterology and hepatology. This same management team held direct responsibility for successfully licensing, developing, and commercializing numerous leading and transformative products for the gastroenterology and hepatology community, their patients and caregivers.
William P. Forbes, Pharm.D., Founder & President and Chief Executive Officer
As the Founder & President, CEO of Vivelix Pharmaceuticals, Bill brings over 25 years of acknowledged, executive leadership experience and skills to Vivelix Pharmaceuticals.
Prior to founding Vivelix, Bill served as President, Medical, Research & Development and Chief Development Officer of Salix Pharmaceuticals until its sale to Valeant Pharmaceuticals in 2015.
As a corporate officer and head of Medical and R&D his responsibilities included areas of corporate communication, governance, compliance, planning, operations, strategy and management. During his tenure at Salix, Bill successfully guided 12 FDA approvals which contributed to the tremendous increase in value of the company over this time with a market capitalization of ~$500 M in 2005 to ~$11 B when it was acquired in April 2015.
Prior to Salix, Bill served as Vice President of Clinical Development and Regulatory Affairs of Metabasis (2002-2004) and in increasing positions of responsibility at Otsuka (1991-2002) and Glaxo (1989-1991).
During his diverse career, Bill has contributed to the approval of numerous marketing applications by health authorities including sNDAs and NDAs for: XIFAXAN550® (HE in CLD 2010, IBS 2015), RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016), RUCONEST® (HAE 2015), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), GIAZO® (Acute UC, 2012), METOZOLV ODT® (Gastroparesis, 2009), APRISO® (Maintenance of Remission in UC, 2008), OSMOPREP® and MOVIPREP® (Bowel cleansing for colonoscopy, both 2006), COLAZAL® (Pediatric use in Acute UC, 2005), PLETAL® (Intermittent Claudication in PAD, 1999).
Bill received his Doctor of Pharmacy at Creighton University in 1987, where he was also a Cardiovascular Research Fellow and Clinical Research Fellow (1987-1989). As an experienced researcher, Bill has authored or co-authored over 48 published manuscripts.
Enoch B. Bortey, Ph.D., Founder & Chief Development Officer
In his role as Chief Development Officer, Enoch brings more than 24 years pharmaceutical experience to Vivelix, including experience in global project management, statistical and clinical operations support for phases I-IV clinical trials in the areas of vaccines, gastroenterology, central nervous system, respiratory, drug delivery systems, anti-infectives, cardiovascular, and bone disease.
Before joining Vivelix, Enoch served as the Vice President, Clinical Biostatistics and Data Systems for BioDelivery Systems International where he was responsible for global design and development of the biostatistics function, translating the development strategies into tactical plans to support product development objectives.
Prior to his tenure at BioDelivery Systems, Enoch was the Senior Vice President, Clinical Operations and Biometrics for Salix Pharmaceuticals, Inc. where he contributed to the approval of numerous marketing applications by health authorities including sNDAs and NDAs for: XIFAXAN550® (HE in CLD 2010, IBS 2015), RELISTOR® (OIC 2014), RUCONEST® (HAE 2015), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), GIAZO® (Acute UC, 2012), METOZOLV ODT® (Gastroparesis, 2009), and APRISO® (Maintenance of Remission in UC, 2008).
Enoch has authored and co-authored 24 published articles and has led statistical efforts for regulatory filings (including European submissions), participated in FDA Advisory Committee Meetings and several other meetings with the FDA and European regulatory authorities.
Enoch earned a B.Sc. in Mathematics from the University of Science and Technology, Kumasi, Ghana; a M.Sc. Statistics from Queen's University, Kingston, Ontario, Canada, and a Ph.D. in Biostatistics from the Medical College of Virginia, Virginia Commonwealth University.
Craig A. Paterson, M.D., M.Sc., M.B.A., Founder & Chief Medical Officer
Craig A. Paterson is Founder & Chief Medical Officer of Vivelix Pharmaceuticals. An experienced pharmaceutical executive, Craig brings over 25 years of combined clinical practice, research and drug development experience. His background includes leadership roles as an academic surgeon at McMaster University and an Associate Professor and Chief of Colon and Rectal Surgery at the University of Massachusetts, as well as a pharmaceutical resume’ that includes clinical research, drug development, lifecycle planning, and strategic portfolio management.
Prior to his role at Vivelix, Craig has held positions of increasing responsibility including Chief Medical Officer where he has provided leadership as well as medical and scientific oversight for R&D functions including clinical development, clinical operations, biometrics, drug safety, medical writing and medical affairs.
At Salix Pharmaceuticals he held leadership roles in Medical and Clinical Development, including the role of Senior Vice President, Medical & Clinical Development prior to the company’s acquisition. Craig contributed to the approval of numerous marketing applications by health authorities while at Salix including sNDAs and NDAs for: XIFAXAN550® (IBS 2015), RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016), RUCONEST® (HAE 2015), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012) and GIAZO® (Acute UC, 2012). He also led all R&D and medical integration activities associated with the acquisition of Santarus, Inc.
Craig obtained his undergraduate degree in chemistry, Doctor of Medicine and a Master of Science degree in physiology and pharmacology all at McMaster University and in 2006 earned his M.B.A. at the University of Tennessee. He completed a General Surgery Residency at McMaster University as well as a fellowship in Colon and Rectal Surgery at the Mayo Clinic.
Pamela L. Golden, Ph.D., Founder & Vice President, Nonclinical and Clinical Pharmacology
As Founder & Vice President, Nonclinical and Clinical Pharmacology, Pam brings over 17 years of nonclinical and clinical pharmacology expertise in the pharmaceutical industry. Pam earned her B.S. in Pharmacy and Ph.D. in Pharmaceutics from The University of North Carolina at Chapel Hill, followed by postdoctoral training at the UCLA School of Medicine and an assistant professorship at the Medical University of South Carolina.
During her career, Pam has contributed to eight IND submissions and seven NDA/sNDA approvals, served as an editorial advisory board member and reviewer for multiple scientific publications, and has authored or co-authored 23 peer-reviewed publications.
Prior to Vivelix, Pam served as Associate Vice President, Nonclinical and Clinical Pharmacology at Salix Pharmaceuticals where she contributed to the regulatory approvals of multiple GI and hepatology products, including XIFAXAN550® (HE in CLD 2010, IBS 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), UCERIS® RECTAL FOAM (Distal UC 2015), and RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016). Prior to Salix, Pam held positions of increasing responsibility at DuPont Pharmaceuticals and GlaxoSmithKline, working in therapeutic areas including neurology and anti-infectives.
Shane Barton, Vice President, Accounting and Controller
As Vice President, Accounting and Controller, Shane Barton has responsibility for accounting, finance, tax and human resources. He has more than 16 years of combined experience, in both public and corporate accounting, primarily focused on the life sciences industry.
Prior to joining Vivelix Pharmaceuticals, Shane spent over 7 years at Cempra Pharmaceuticals serving as Vice President, Accounting & Controller, Chief Accounting Officer. He played a key role in Cempra becoming a public company on the NASDAQ in February 2012 and supported fundraising efforts for over $500 million in new capital. He began his career in public accounting where he worked with both public and private audit clients in various industries.
Prior to his professional career, Shane served as a paratrooper in the 82nd Airborne Division of the U.S. Army. He holds a bachelor of science in accounting from Appalachian State University and is also licensed as a Certified Public Accountant in North Carolina.
Christopher A. Martin, M.S., Founder & Executive Director, CMC Operations
Christopher Martin is Founder & Executive Director, CMC Operations of Vivelix Pharmaceuticals. Chris is known in the industry as a results-driven Pharmaceutical R&D expert with nearly 20 years of industry experience in key technical, management and leadership positions with emphasis in pharmaceutical formulation and process development, analytical development, clinical and commercial-scale manufacturing, CMC regulatory operations, and quality assurance management.
Prior to Vivelix, Chris contributed to the success of Salix for 10 years through his roles in directing CMC regulatory activities for all Salix products, including sNDAs and NDAs for: XIFAXAN550® (HE in CLD 2010, IBS 2015), RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), GIAZO® (Acute UC, 2012), METOZOLV ODT® (Gastroparesis, 2009), APRISO® (Maintenance of Remission in UC, 2008), OSMOPREP® and MOVIPREP® (Bowel cleansing for colonoscopy, both 2006) and COLAZAL® (Pediatric use in Acute UC, 2005), amongst others.
Chris also held laboratory and analytical management positions at Varian, Inc. and AAI International.
Chris acquired his undergraduate degree in biology at the University of North Carolina, Chapel Hill, and his Master’s Degree in Marine Biology at the University of North Carolina, Wilmington where he also served as a graduate assistant.
Corey M. Hansen, M.B.A., Executive Director, Strategic Planning & Business Development
As Executive Director of Strategic Planning & Business Development, Corey brings greater than 20 years of increasing responsibilities in business development, competitive intelligence, marketing research, business analytics and strategic planning. Prior to Vivelix, Corey was Sr. Director, Global Business Intelligence at United Therapeutics. In that role, Corey provided key input into the go/no go decisions for potential acquisition candidates. Prior to United Therapeutics, Corey served as Sr. Director, Marketing Research and Strategic Analysis at Salix Pharmaceuticals where he managed commercial analytics support to sales & marketing, business development, finance, accounting, legal, medical, R&D, regulatory and managed markets. While at Salix, Corey was involved in assessing a variety of corporate development opportunities, including acquisitions of Oceana Therapeutics and Santarus, inversion deal with Cosmo Pharmaceuticals, and eventual company sale to Valeant Pharmaceuticals.
Corey’s previous experience includes tenures at Dey Pharma (Mylan Specialty Division), Frost & Sullivan Growth Consulting, Hatteras Venture Partners and Miravant Pharmaceuticals.
Corey has a B.S. in Pharmacology from the University of California, Santa Barbara, and earned an M.B.A. from the University of North Carolina, Chapel Hill, Kenan-Flagler Business School.